Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARAV Stock Summary
In the News
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago.
Why Is Aravive (ARAV) Stock Down 58% Today?
Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV stock today is that its Phase 3 AXLerate-OC trial did not meet its primary endpoint.
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC).
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essentially take the opposite side of the bearish bet.
Aravive To Participate in the Jefferies Global Healthcare Conference
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight updated results from the Phase 2 portion of the trial in patients with advanced or metastatic ccRCC with or without prior line(s) of therapy, including immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma (PDAC) will be published in the 2023 ASCO Annual Meeting Proceedings.
7 Short-Interest Stocks to Target for Explosive Gains
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks.
What Makes Aravive (ARAV) a New Buy Stock
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy
Although the concept of gambling on short-squeeze stocks present risks, certain market ideas drive hedge funds crazy. By this statement, I'm referring to companies that speculators believe in their hearts should tumble for various reasons.
ARAV Financial details
ARAV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.19 | 0.41 | 0.36 | 0.37 | 0.25 | |
Net income per share | -10.64 | -1.75 | -2.17 | -1.9 | -2.22 | |
Operating cash flow per share | -4.08 | -1.47 | -0.77 | -1.6 | -1.79 | |
Free cash flow per share | -4.37 | -1.47 | -0.77 | -1.6 | -1.79 | |
Cash per share | 7.95 | 5.62 | 3.83 | 2.96 | 1.48 | |
Book value per share | 8.36 | 5.96 | 3.04 | 2.1 | 0.29 | |
Tangible book value per share | 8.31 | 5.94 | 3.04 | 2.1 | 0.29 | |
Share holders equity per share | 8.36 | 5.96 | 3.04 | 2.1 | 0.29 | |
Interest debt per share | 1.15 | 1.09 | 0.67 | 0.43 | 0.3 | |
Market cap | 25.24M | 158.42M | 89.06M | 43.95M | 48.01M | |
Enterprise value | -24.43M | 103.52M | 37.03M | -9.1M | 594.04K | |
P/E ratio | -0.33 | -7.82 | -2.6 | -1.15 | -0.59 | |
Price to sales ratio | 18.41 | 33.33 | 15.67 | 5.91 | 5.25 | |
POCF ratio | -0.86 | -9.27 | -7.32 | -1.37 | -0.74 | |
PFCF ratio | -0.8 | -9.27 | -7.32 | -1.37 | -0.74 | |
P/B Ratio | 0.42 | 2.29 | 1.85 | 1.04 | 4.51 | |
PTB ratio | 0.42 | 2.29 | 1.85 | 1.04 | 4.51 | |
EV to sales | -17.82 | 21.78 | 6.51 | -1.22 | 0.07 | |
Enterprise value over EBITDA | 0.69 | -5.68 | -1.93 | 0.22 | -0.01 | |
EV to operating cash flow | 0.83 | -6.06 | -3.04 | 0.28 | -0.01 | |
EV to free cash flow | 0.78 | -6.06 | -3.04 | 0.28 | -0.01 | |
Earnings yield | -3.02 | -0.13 | -0.38 | -0.87 | -1.69 | |
Free cash flow yield | -1.24 | -0.11 | -0.14 | -0.73 | -1.36 | |
Debt to equity | 0.1 | 0.18 | 0.22 | 0.21 | 0.59 | |
Debt to assets | 0.08 | 0.15 | 0.16 | 0.13 | 0.1 | |
Net debt to EBITDA | 1.4 | 3.01 | 2.71 | 1.31 | 0.67 | |
Current ratio | 29.42 | 26.25 | 5.65 | 3.22 | 2.73 | |
Interest coverage | -31.05 | 0 | 0 | 0 | -15.4 | |
Income quality | 0.38 | 0.94 | 0.4 | 0.82 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 19.98 | 2.88 | 2.3 | 1.42 | 1.43 | |
Research and developement to revenue | 8.08 | 2.7 | 3.1 | 5.04 | 7.33 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.07 | 0 | 0 | 0 | 0 | |
Capex to revenue | -1.54 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.99 | 0 | 0 | 0 | -0.01 | |
Stock based compensation to revenue | 11.77 | 0.72 | 0.35 | 0.3 | 0.28 | |
Graham number | 44.74 | 15.31 | 12.19 | 9.48 | 3.83 | |
ROIC | -1.05 | -0.26 | -0.51 | -0.69 | -3.58 | |
Return on tangible assets | -1.1 | -0.25 | -0.51 | -0.56 | -1.3 | |
Graham Net | 6.64 | 4.65 | 2.67 | 1.67 | 0.04 | |
Working capital | 55.06M | 64.98M | 51.83M | 42.66M | 35.6M | |
Tangible asset value | 59.6M | 68.83M | 47.96M | 42.22M | 10.66M | |
Net current asset value | 47.47M | 54.49M | 43.32M | 36.29M | 4.64M | |
Invested capital | 0.1 | 0.18 | 0.22 | 0.21 | 0.59 | |
Average receivables | 303K | 1.56M | 1.38M | 147.5K | 59K | |
Average payables | 3.77M | 2.26M | 3.7M | 3.74M | 5.71M | |
Average inventory | -311K | -373.5K | 1.01M | 614.5K | -1.42M | |
Days sales outstanding | 161.33 | 192.29 | 16.82 | 1.62 | 3.4 | |
Days payables outstanding | 0 | 73.19 | 99.91 | 25.83 | 47.79 | |
Days of inventory on hand | 0 | -3.55 | 44.58 | -8.97 | -10.47 | |
Receivables turnover | 2.26 | 1.9 | 21.7 | 225.52 | 107.49 | |
Payables turnover | 0 | 4.99 | 3.65 | 14.13 | 7.64 | |
Inventory turnover | 0 | -102.69 | 8.19 | -40.67 | -34.85 | |
ROE | -1.27 | -0.29 | -0.71 | -0.9 | -7.59 | |
Capex per share | -0.29 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.16 | 0.02 | 0.02 | 0.01 | 0.04 | |
Net income per share | -0.48 | -0.61 | -1.08 | 0.18 | 0.28 | |
Operating cash flow per share | -0.62 | -0.23 | -0.23 | -0.18 | -0.13 | |
Free cash flow per share | -0.62 | -0.23 | -0.23 | -0.18 | -0.13 | |
Cash per share | 0.91 | 0.85 | 0.47 | 0.18 | 0.11 | |
Book value per share | 0.49 | 0.17 | -0.51 | -0.2 | 0.02 | |
Tangible book value per share | 0.49 | 0.17 | -0.51 | -0.2 | 0.02 | |
Share holders equity per share | 0.49 | 0.17 | -0.51 | -0.2 | 0.02 | |
Interest debt per share | 0.16 | 0.1 | 0.49 | 0.03 | 0.03 | |
Market cap | 24.93M | 83.08M | 151.43M | 125.54M | 10.04M | |
Enterprise value | 1.68M | 35.66M | 119.02M | 110.15M | 3.94M | |
P/E ratio | -0.43 | -0.54 | -0.46 | 1.74 | 0.12 | |
Price to sales ratio | 5.03 | 56.36 | 101.56 | 98.54 | 3.64 | |
POCF ratio | -1.32 | -5.84 | -8.53 | -7.11 | -1.02 | |
PFCF ratio | -1.32 | -5.83 | -8.53 | -7.11 | -1.02 | |
P/B Ratio | 1.66 | 7.8 | -3.92 | -6.34 | 5.9 | |
PTB ratio | 1.66 | 7.8 | -3.92 | -6.34 | 5.9 | |
EV to sales | 0.34 | 24.19 | 79.83 | 86.46 | 1.43 | |
Enterprise value over EBITDA | -0.1 | -1.8 | 7.67 | -2.63 | -0.1 | |
EV to operating cash flow | -0.09 | -2.5 | -6.7 | -6.24 | -0.4 | |
EV to free cash flow | -0.09 | -2.5 | -6.7 | -6.24 | -0.4 | |
Earnings yield | -0.59 | -0.46 | -0.54 | 0.14 | 2.11 | |
Free cash flow yield | -0.76 | -0.17 | -0.12 | -0.14 | -0.98 | |
Debt to equity | 0.31 | 0.59 | -0.09 | -0.15 | 1.43 | |
Debt to assets | 0.11 | 0.1 | 0.08 | 0.12 | 0.19 | |
Net debt to EBITDA | 1.42 | 2.39 | -2.09 | 0.37 | 0.16 | |
Current ratio | 1.59 | 2.73 | 1.93 | 1.55 | 0.98 | |
Interest coverage | -112.57 | 90.29 | 0.46 | 0 | 0 | |
Income quality | 1.21 | 0.49 | 0.36 | -0.98 | -0.46 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.57 | 2.3 | 2.34 | 2.41 | 1.07 | |
Research and developement to revenue | 3.77 | 12.18 | 10.67 | 8.47 | 3.17 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.01 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.05 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.13 | 0.39 | 0.46 | 0.6 | 0.11 | |
Graham number | 2.31 | 1.52 | 3.53 | 0.9 | 0.37 | |
ROIC | -0.64 | -1.25 | -0.8 | 2.41 | -3.25 | |
Return on tangible assets | -0.35 | -0.62 | -1.91 | 0.7 | 1.63 | |
Graham Net | 0.17 | 0.02 | -0.6 | -0.27 | -0.04 | |
Working capital | 14.11M | 35.6M | 18.87M | 7.82M | -215K | |
Tangible asset value | 15.04M | 10.66M | -38.61M | -19.82M | 1.7M | |
Net current asset value | 10.66M | 4.64M | -42.59M | -23.51M | -1.79M | |
Invested capital | 0.31 | 0.59 | -0.09 | -0.15 | 1.43 | |
Average receivables | 3M | 3.04M | 42.5K | 0 | 0 | |
Average payables | 6.76M | 8.79M | 9.28M | 6.84M | 4.66M | |
Average inventory | 0.5 | -960.5K | -960.5K | 0 | 0 | |
Days sales outstanding | 108.96 | 5.19 | 0 | 0 | 0 | |
Days payables outstanding | 42.53 | 43.94 | 55.39 | 32.47 | 55.91 | |
Days of inventory on hand | 0 | -9.63 | 0 | 0 | 0 | |
Receivables turnover | 0.83 | 17.34 | 0 | 0 | 0 | |
Payables turnover | 2.12 | 2.05 | 1.62 | 2.77 | 1.61 | |
Inventory turnover | 18.67M | -9.35 | 0 | 0 | 0 | |
ROE | -0.97 | -3.6 | 2.12 | -0.91 | 12.48 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ARAV Frequently Asked Questions
What is Aravive, Inc. stock symbol ?
Aravive, Inc. is a US stock , located in Houston of Tx and trading under the symbol ARAV
Is Aravive, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $0.25. The lowest prediction is $0.25 and the highest is $0.25
What is ARAV stock prediction ?
What is Aravive, Inc. stock quote today ?
Aravive, Inc. stock price is $0.0401 today.
Is Aravive, Inc. stock public?
Yes, Aravive, Inc. is a publicly traded company.